Alvotech further strengthens liquidity by securing term loan facility of $75 millionGlobeNewsWire • 07/01/26
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private PlacementGlobeNewsWire • 06/18/26
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary SharesGlobeNewsWire • 06/18/26
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private PlacementGlobeNewsWire • 06/16/26
Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day TranscriptSeeking Alpha • 06/10/26
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®GlobeNewsWire • 06/08/26
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®GlobeNewsWire • 06/04/26
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq IcelandGlobeNewsWire • 06/01/26
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/14/26
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik FacilityGlobeNewsWire • 05/11/26
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar PlayerSeeking Alpha • 04/10/26